Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;9(7):103620.
doi: 10.1016/j.esmoop.2024.103620. Epub 2024 Jun 18.

Concurrent antibody-drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials

Y Koide  1 , T Kodaira  2
Affiliations

Concurrent antibody-drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials

Y Koide et al. ESMO Open. 2024 Jul.
No abstract available

PubMed Disclaimer

References

    1. Hurvitz S.A., Hegg R., Chung W.-P., et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401:105–117. - PubMed
    1. Hurvitz S.A., Kim S.-B., Chung W.-P., et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. ESMO Open. 2024;9 - PMC - PubMed
    1. Lin N.U., Murthy R.K., Abramson V., et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 2023;9:197–205. - PMC - PubMed
    1. Salvestrini V., Kim K., Caini S., et al. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: a systematic review and meta-analysis. Radiother Oncol. 2023;186 - PubMed
    1. Koide Y., Nagai N., Adachi S., et al. Impact of concurrent antibody–drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study. J Neurooncol. 2024 doi: 10.1007/s11060-024-04681-8. - DOI - PubMed

MeSH terms